SCHEMBL4675216

SCHEMBL4675216

Cc1ccc(Cc2c[nH]c(C(=O)C=C(O)C(=O)O)c2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 1/20 0.40
DAO P14920 2/20 0.37
LMNA P02545 3/20 0.35
CTBP2 P56545 1/20 0.34
AKR1C4 P17516 2/20 0.34
AKR1C3 P42330 2/20 0.34
AKR1C2 P52895 1/20 0.34
AKR1C1 Q04828 1/20 0.34
ALDH1A1 P00352 3/20 0.33
HTT P42858 3/20 0.33
NPSR1 Q6W5P4 3/20 0.33
PKM P14618 2/20 0.33
HPGD P15428 2/20 0.33
ATM Q13315 2/20 0.33
NLRP1 Q9C000 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
MEN1 O00255 1/20 0.33
NTSR1 P30989 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4675213 1.00 SRD5A2 (0.40) SRD5A2DAOLMNACTBP2AKR1C4
SCHEMBL4675566 0.87 GAA (0.39) DAOLMNAALDH1A1PKMMEN1
SCHEMBL4675568 0.87 GAA (0.39) DAOLMNAALDH1A1PKMMEN1
SCHEMBL4674577 0.87 KMT2A (0.49) SRD5A2DAOLMNAAKR1C3ALDH1A1
SCHEMBL4674575 0.87 KMT2A (0.49) SRD5A2DAOLMNAAKR1C3ALDH1A1
SCHEMBL4670509 0.86 ALDH1A1 (0.38) DAOALDH1A1TDP1
SCHEMBL4670512 0.86 ALDH1A1 (0.38) DAOALDH1A1TDP1
SCHEMBL4675878 0.86 DAO (0.37) DAOLMNACTBP2ALDH1A1PKM
SCHEMBL4675875 0.86 DAO (0.37) DAOLMNACTBP2ALDH1A1PKM
SCHEMBL4676087 0.86 LTA4H (0.42) DAOCTBP2AKR1C3AKR1C2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 SRD5A2 371/4885DAO 661/4885LMNA 659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.